Biagon Inc.
- Biotech or pharma, therapeutic R&D
- Academic, tech transfer
Biagon's first-in-class machine learning algorithm to screen for and design biased agonists provides unprecedented opportunity for GPCR targets. Whether through internal or partnered programs, we are passionate about exploiting cell signaling to open therapeutic windows for indications ranging from heart failure to neurodegenerative disease.
At BIO, we are looking forward to introductions to potential in-licensing partners, discovery-based partners, and investors.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}